Evotec announces sale of API manufacturing facility to Monacum Partners
New ownership committed to maintaining and growing the business
Advertisement
Evotec SE has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec’s “Priority Reset” initiative launched in April 2024, which aims to foster profitable growth by refining the company’s operational footprint and focusing on its primary growth sectors and core competencies.
Evotec DS in Halle/Westphalia is a specialized CDMO (Contract Development and Manufacturing Organization) with a strong foundation in chemical APIs, intermediates, and building blocks, which provides an end-to-end service portfolio, encompassing development to commercial-scale manufacturing.
The transaction presents an opportunity for Evotec DS to achieve its growth ambitions under new ownership. Under the agreement, all business operations and the entire workforce at Evotec DS will transition to Monacum Partners and continue business as DAPIN GmbH (Deutsche API & Intermediates). Financial terms of the transaction were not disclosed.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Ceva Animal Health invests in new 7,000 m² vaccine manufacturing facility to expand global production capacity

Rentschler Biopharma announces largest single investment at its headquarters in Germany - Construction of a new buffer media station in Laupheim

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Waldner: Ground-breaking for new powder coating plant

Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

ProBioGen expands protein and virus manufacturing to drive continued growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Sensirion opens additional production building in Debrecen

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus
